Skip to main content
CAI logo

CAI · Caris Life Sciences, Inc. · Financials

Track CAI — free
$17.58 -0.96 (-5.18%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$5.04B
Shares
286.78M
Volume · Nov 20 4.57M Avg daily vol (3M) 4.64M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$812.03M +97%
FY2025 Revenue FY2023–FY2025
Net Income
-$68.09M +75.8%
FY2025 Net Income FY2023–FY2025
Operating Margin
5.56% +67.9pp
FY2025 Operating Margin FY2023–FY2025
Diluted EPS
-$3.22 +69.8%
FY2025 Diluted EPS FY2023–FY2025
Operating Cash Flow
$83.16M +133.9%
FY2025 Operating Cash Flow FY2023–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2026 (G) TTM FY2025 FY2024 FY2023
$1.04B – $1.05B $1.05B $812.03MG $412.26M $306.13M
— $129.36M $101.58M $113.92M $116.88M
— $202.81M $167.51M $152.6M $142.93M
— $252.04M $224.97M $169.39M $149.05M
— $22.44M $22.62M $48.91M $49M
— $908.2M $766.92M $669.38M $625.68M
— $139.94M $45.11M -$257.12M -$319.55M
— — 5.56% -62.37% -104.38%
— $162.37M $67.73M -$208.21M -$270.55M
— $42.64M $56.85M $50.03M $31.61M
— -$42.36M -$113.2M -$24.77M -$21.86M
— $97.57M -$68.09M -$281.89M -$341.42M
— $1.51M $0 $0 $0
— $96.06M -$68.09M -$281.89M -$341.42M
— — -8.38% -68.38% -111.53%
— $96.06M -$537.96M -$378.26M -$462.53M
— $95.21M -$67.36M -$281.9M -$342.9M
USD/shares — $8.28 -$3.22 -$10.66 -$13.24
USD/shares — $8.29 -$3.22 -$10.66 -$13.24
shares — — 167.21M 35.5M 34.94M
shares — — 167.21M 35.5M 34.94M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2025: $113K in buybacks.

Debt Profile

Completed filing coverage through Apr 2, 2026

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-09-30 USD 6,287,000 10-Q filed 2026-11-04
Long-term debt, including current maturities 2026-09-30 USD 393,002,000 10-Q filed 2026-11-04
Related accounting measures — not additional borrowing

Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.

Current portion of long-term debt
USD 89,000
Noncurrent debt carrying amount
USD 393,178,000
Noncurrent operating lease liabilities 2026-09-30 USD 63,466,000 10-Q filed 2026-11-04
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

Delayed Draw Facility

TermLoan · Caris Life Sciences, Inc.

Reference: Delayed Draw Facility

Active
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Reported commitment: USD 300,000,000 Reported 2026-04-02 Disclosed facility capacity; the amount drawn and capacity available today are not established.

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-04-02 Commitment USD 300,000,000 Exact source document Parent 8-K filing · 2026-04-02
    The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.
    Issuer evidence: On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, dated as of the Closing Date (the “New Credit Agreement”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.
    Supporting evidence: The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.
    Supporting evidence: The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.

Initial Term Facility

TermLoan · Caris Life Sciences, Inc.

Reference: Initial Term Facility

Active
Original principal
USD 400,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
—

Covenant terms for this agreement are not yet verified.

Documents and filing history
  1. Issuance · 2026-04-02 Original principal USD 400,000,000 Exact source document Parent 8-K filing · 2026-04-02
    The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.
    Issuer evidence: On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, dated as of the Closing Date (the “New Credit Agreement”), by and among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, which consist of funds managed by Blue Owl Capital and Blackstone, and Blue Owl Capital Corporation, as administrative agent for the lenders.
    Supporting evidence: The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.
    Supporting evidence: The New Credit Agreement provides for certain senior secured credit facilities to the Company consisting of (a) an initial term loan in an aggregate principal amount equal to $400,000,000, funded on the Closing Date (the “Initial Term Facility”), (b) a committed delayed draw term loan facility in an aggregate principal amount that may be drawn in one or more tranches not to exceed $300,000,000 in the aggregate (“Delayed Draw Facility”), and (c) an uncommitted incremental facility in an aggregate principal amount not to exceed $500,000,000. The Company’s obligations under the New Credit Agreement are unconditionally and irrevocably guaranteed jointly and severally on a senior basis by certain existing and subsequently acquired direct or indirect subsidiaries of the Company, with certain exceptions as set forth in the New Credit Agreement (each, a “Guarantor”). The Initial Term Facility matures in April 2031 and the Delayed Draw Facility is available through August 2027.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 8.70×
EV/EBIT
—
Peer median 32.76×
P/E (TTM common income)
52.48×
Peer median 22.84×
Price/Sales (TTM)
4.81×
Peer median 11.19×
Price/Book
7.88×
Peer median 3.92×

Peer medians compare against the 186 similar-size Biotechnology companies (of 594 listed).

Valuation over time computed as of each quarter's filing date

EV/Adj. EBITDA uses the company-stated “Adjusted EBITDA”, extracted from the reconciliation in its SEC filings as it existed at each sample date — the company's own non-GAAP definition, not an XBRL-tagged figure. Each point's tooltip names its TTM or fiscal-year basis.

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component FY2025 FY2024 FY2023
Reportable Segment $812,033,000 $412,260,000 $306,128,000

By Geography (USD)

Component FY2025 FY2024 FY2023
United States $801,393,000 $401,836,000 $293,408,000
Non Us $10,640,000 $10,424,000 $12,720,000

By Product & Service (USD)

Component FY2025 FY2024 FY2023
Molecular Profiling Services $766,719,000 $349,115,000 $278,748,000
Pharma Research and Development Services $45,314,000 $63,145,000 $27,380,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component FY2025 FY2024 FY2023
Reportable Segment $45,113,000 -$257,122,000 -$319,551,000

Operating Margin by Segment (%)

Component FY2025 FY2024 FY2023
Reportable Segment 5.6% -62.4% -104.4%
Key facts CIK 2019410 CUSIP 142152107 13F (30d) 312 filings 296 filers Visit website Investor relations